Estrella Immunopharma正式将克利夫兰大学医院医学中心(University Hospitals Cleveland Medical Center)纳为其I/II期Starlight-1临床试验的第四临床中心。该试验专注于B细胞非霍奇金淋巴瘤的治疗。这一扩展标志着公司在推进该疗法临床研究道路上迈出关键一步。
Estrella Immunopharma正式将克利夫兰大学医院医学中心(University Hospitals Cleveland Medical Center)纳为其I/II期Starlight-1临床试验的第四临床中心。该试验专注于B细胞非霍奇金淋巴瘤的治疗。这一扩展标志着公司在推进该疗法临床研究道路上迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.